US 12,378,313 B2
Bispecific binding agents binding to CLDN18.2 and CD3
Matthew Bernett, Pasadena, CA (US); Alex Nisthal, Pasadena, CA (US); and Gregory Moore, Pasadena, CA (US)
Assigned to Xencor, Inc., Pasadena, CA (US)
Filed by Xencor, Inc., Pasadena, CA (US)
Filed on Jul. 5, 2023, as Appl. No. 18/347,361.
Application 18/347,361 is a continuation of application No. 18/062,465, filed on Dec. 6, 2022, granted, now 11,739,145.
Application 18/062,465 is a continuation of application No. PCT/EP2022/066299, filed on Jun. 15, 2022.
Claims priority of application No. PCT/EP2021/066141 (WO), filed on Jun. 15, 2022.
Prior Publication US 2024/0018234 A1, Jan. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/28 (2013.01) [C07K 16/2809 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/92 (2013.01)] 33 Claims
 
1. A bispecific binding agent that binds CLDN18.2 and CD3, the bispecific binding agent comprising:
a first heavy chain variable region (VH) and a first light chain variable region (VL) wherein said first VH and said first VL bind to CLDN18.2;
a second VH and a second VL wherein said second VH and said second VL bind to CLDN18.2;
a third VH and a third VL wherein said third VH and said third VL bind to CD3;
wherein the first and second VH each comprise a CDR1 comprising the amino acid sequence SYWIN (SEQ ID NO: 32), a CDR2 comprising the amino acid sequence NIYPSDSYTNYNQKFQG (SEQ ID NO: 33), and a CDR3 comprising the amino acid sequence SWRGNSFDY (SEQ ID NO: 34);
wherein the first and second VL each comprise a CDR1 comprising the amino acid sequence KSSQSLLNSGNQKNYLT (SEQ ID NO: 35), a CDR2 comprising the amino acid sequence WASTRES (SEQ ID NO: 36), and a CDR3 comprising the amino acid sequence QNDYSYPFT (SEQ ID NO: 37);
wherein the third VH comprises a CDR1 comprising the amino acid sequence TYAMN (SEQ ID NO: 43), a CDR2 comprising the amino acid sequence RIRSKANNYATYYADSVKG (SEQ ID NO: 50), and a CDR3 comprising the amino acid sequence HGNFGDSYVSWFAY (SEQ ID NO: 45); and
wherein the third VL comprises a CDR1 comprising the amino acid sequence GSSTGAVTTSNYAN (SEQ ID NO: 46), a CDR2 comprising the amino acid sequence GTNKRAP (SEQ ID NO: 47), and a CDR3 comprising the amino acid sequence ALWYSNHWV (SEQ ID NO: 48).